Eye Pharma

Eye Pharma is a private, Italy-based biopharmaceutical company dedicated to advancing ophthalmology treatments through targeted R&D. The company is developing an innovative platform leveraging liposomal technology to enhance drug delivery and efficacy for ocular surface diseases, with its lead program, ERISnp®, targeting dry eye syndrome. While currently in the development stage and likely pre-revenue, Eye Pharma positions itself as an avant-garde player aiming to address unmet medical needs with high-value therapeutic solutions. Its strategy involves collaborations with top research centers and a commitment to ecological sustainability.

Liposomal drug delivery technology for enhanced ocular surface retention and efficacy of therapeutic formulations.

Eye Pharma competes in the crowded dry eye disease market against major pharmaceutical companies (e.g., Allergan/AbbVie, Novartis, Santen) and specialized biotechs. Its differentiation relies on its liposomal formulation technology and natural compound-based approach, aiming to offer prolonged efficacy and address inflammation.